Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

ENOV - Enovis Corporation Последние новости | Finranks

Home

ENOV

E

Enovis Corporation (ENOV)

NYQ – Цена в реальном времени. Валюта: USD

21.82

-1.55 (-6.63%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

22.02

+0.20 (0.94%)

После закрытия: Mar 27, 2026, 7:50 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Wall Street Analysts See a 100.71% Upside in Enovis (ENOV): Can the Stock Really Move This High?

Wall Street Analysts See a 100.71% Upside in Enovis (ENOV): Can the Stock Really Move This High?

The consensus price target hints at a 100.7% upside potential for Enovis (ENOV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Royce Small-Cap Fund FY 2025: What Worked

Royce Small-Cap Fund FY 2025: What Worked

Five of the Fund's 10 equity sectors made a positive impact on calendar year performance, led by Industrials, Financials, and Information Technology. Alamos Gold's positive earnings outlook, a renewed stock buyback program, and rising gold prices all helped its stock to climb throughout 2025. Management reported a 48% increase in total revenue for 1Q25 compared to 1Q24, driven by OCS liver and heart transplants.

Wall Street Analysts Think Enovis (ENOV) Could Surge 76.62%: Read This Before Placing a Bet

Wall Street Analysts Think Enovis (ENOV) Could Surge 76.62%: Read This Before Placing a Bet

The mean of analysts' price targets for Enovis (ENOV) points to a 76.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Enovis Corporation (ENOV) Q4 2025 Earnings Call Transcript

Enovis Corporation (ENOV) Q4 2025 Earnings Call Transcript

Enovis Corporation (ENOV) Q4 2025 Earnings Call Transcript

One Fund Bet $5 Million on Enovis Stock Last Quarter. Shares Surged 14% Post-Earnings

One Fund Bet $5 Million on Enovis Stock Last Quarter. Shares Surged 14% Post-Earnings

Front Street added 156,069 shares of Enovis in the fourth quarter. The quarter-end position value increased by $3.40 million, reflecting both trading activity and share price changes.

Enovis (ENOV) Q4 Earnings Beat Estimates

Enovis (ENOV) Q4 Earnings Beat Estimates

Enovis (ENOV) came out with quarterly earnings of $0.95 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.98 per share a year ago.

Update: Enovis Announces Fourth Quarter and Full Year 2025 Results

Update: Enovis Announces Fourth Quarter and Full Year 2025 Results

Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.

Видео

No Data

There is no data to display

Пресс-релизы

Update: Enovis Announces Fourth Quarter and Full Year 2025 Results

Update: Enovis Announces Fourth Quarter and Full Year 2025 Results

Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.

Enovis Announces Fourth Quarter and Full Year 2025 Results

Enovis Announces Fourth Quarter and Full Year 2025 Results

Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.

Enovis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Enovis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Dallas TX, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, UT. About Enovis Enovis™ (NYSE: ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically differentiated solutions that enhance patient outcomes and restore motion for life.

Enovis to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Enovis to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dallas, TX, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will meet with investors at the 44th Annual J.P. Morgan Healthcare Conference with a presentation scheduled for Monday, January 12th, 2026, at 4:30 p.m.